iTolerance

About iTolerance

iTolerance, Inc. is a data-driven and patient-centric regenerative medicine company focused on enabling implantable tissue, organoid, or cell therapy without the need for lifelong immunosuppression. The company leverages its proprietary technology platform to advance a pipeline of product candidates aimed at curing diseases. Their flagship product, iTOL 100, is a synthetic form of the naturally occurring protein FasL, combined with a synthetic hydrogel microparticle microgel. This combination allows for convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance, eliminating the need for lifelong immunosuppression.

iTolerance operates in the biotechnology sector, serving patients who require regenerative therapies. The company’s business model revolves around developing and commercializing its proprietary technology and product candidates. Revenue is generated through the sale of these therapies and potentially through partnerships and licensing agreements.

The market for iTolerance includes healthcare providers, research institutions, and patients in need of advanced regenerative treatments. The company aims to address significant unmet medical needs by offering innovative solutions that improve patient outcomes and reduce the burden of chronic immunosuppression.